Noxopharm initiates Phase Ib trial of NOX66 for prostate cancer

Australia-based Noxopharm has initiated a Phase Ib clinical trial of NOX66 in metastatic castrate-resistant prostate cancer patients who do not have remaining standard therapeutic options.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news

Related Links:

ConclusionsThis is the first nationwide study in Spain to report long-term outcomes of patients with intermediate-risk PCa treated with EBRT. Survival outcomes were good, with a low incidence of both acute and late toxicity. Patients with unfavourable risk characteristics had significantly lower 5- and 10-year disease-free survival rates. ADT and radiotherapy dose  ≥ 74 Gy were both significant predictors of treatment outcomes.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
We present a 71-year-old Japanese man with metastasis prostate cancer that, during medical castration therapy, had torsades de pointes (TdP) with a QT prolongation and ventricular fibrillation (VF). His QT interval diminished after discontinuing the medical castration, and he developed no further VF recurrences for 15 months. Medical castration is a rare but possible trigger of TdP with QT prolongation and VF. PMID: 30518719 [PubMed - as supplied by publisher]
Source: International Heart Journal - Category: Cardiology Tags: Int Heart J Source Type: research
Conclusion: The increases in the incidence of different types of cancer in the past decade could be due to the revolutionary change in socioeconomic status that has occurred in Saudi Arabia; therefore, a national plan should be established for cancer prevention, screening and therapy. Concerning mortality, the decrease in its percentage among elderly people could be due to biological factors that should be investigated in the future. PMID: 30520511 [PubMed - in process]
Source: Saudi Medical Journal - Category: Middle East Health Tags: Saudi Med J Source Type: research
Publication date: Available online 8 December 2018Source: European UrologyAuthor(s): Tommy Nyberg, Koveela Govindasami, Goska Leslie, Tokhir Dadaev, Elizabeth Bancroft, Holly Ni Raghallaigh, Mark N. Brook, Nafisa Hussain, Diana Keating, Andrew Lee, Romayne McMahon, Angela Morgan, Andrea Mullen, Andrea Osborne, Reshma Rageevakumar, The UK Genetic Prostate Cancer Study Collaborators, Zsofia Kote-Jarai, Rosalind Eeles, Antonis C. AntoniouAbstractBackgroundThe homeobox B13 (HOXB13) G84E mutation has been recommended for use in genetic counselling for prostate cancer (PCa), but the magnitude of PCa risk conferred by this mutati...
Source: European Urology - Category: Urology & Nephrology Source Type: research
ConclusionsThe Y-chromosomal lncRNA TTTY15 was upregulated in most PCa tissues and could promote PCa progression by sponging let-7.Patient summaryWe found that TTTY15 levels were frequently elevated in prostate cancer (PCa) tissues compared with those in paracancerous normal tissues in a large group of PCa patients, and we observed a tumour suppressive effect after TTTY15 knockout using CRISPR/Cas9. These results may have therapeutic implications for PCa patients.
Source: European Urology - Category: Urology & Nephrology Source Type: research
Conclusions The clinical implementation of the standardized care pathway is described as a straight path through care, but patients described their experiences as walking a tightrope. Lack of information, especially about cancer treatment and its adverse effects, was the most common experience. Implications for Practice Our findings indicate areas where further healthcare tools could improve patient experiences of cancer treatment. This could include offering individualized information and tools to increase patient empowerment, as well as patient/caregiver collaboration (co-care).
Source: Cancer Nursing - Category: Nursing Tags: ARTICLES: ONLINE ONLY Source Type: research
In conclusion, ICA-1s is stable, shows low toxicity, and is a potential therapeutic for prostate carcinoma tumors.
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: PRECLINICAL REPORTS Source Type: research
AbstractOral enzalutamide (Xtandi®), a second generation androgen receptor inhibitor, is indicated for the treatment of castration-resistant prostate cancer (CRPC) in numerous countries worldwide, with specific indications in this patient population varying between individual countries. Based on extensive experience in the clinical trial and/or real-world settings, oral enzalutamide 160 mg once daily is an effective and generally well tolerated treatment in a broad spectrum of patients with CRPC, including in nonmetastatic and metastatic disease and in chemotherapy-naive and -experienced metastatic CRPC. Enzalutamide i...
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
Condition:   Prostate Cancer Intervention:   Drug: Ga-68 PSMA11 Sponsor:   Mayo Clinic Not yet recruiting
Source: - Category: Research Source Type: clinical trials
Conclusion Positive 11C-choline PET/CT result had an important effect in the therapeutic management of patients with PCa and BR, leading to a change in the planned approach in two (66.1%) out of three patients. In addition, in 4.5% of the patients, the 11C-choline PET/CT allowed the detection of a second malignancy.
Source: Nuclear Medicine Communications - Category: Nuclear Medicine Tags: ORIGINAL ARTICLES Source Type: research
More News: Australia Health | Cancer | Cancer & Oncology | Clinical Trials | Pharmaceuticals | Prostate Cancer